Levosimendan attenuates pulmonary vascular remodeling

Intensive Care Medicine

Volumn 37, Issue 8, 2011, Pages 1368-1377

  Revermann, M ^a,b   Schloss, M ^a   Mieth, A ^a   Babelova, A ^a   Schroder K ^a   Neofitidou, S ^a   Buerkl, J ^a   Kirschning, T ^b   Schermuly, R T ^c   Hofstetter, C ^b   Brandes, R P ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Levosimendan; Potassium channel; Pulmonary arterial hypertension; Vascular remodeling

Indexed keywords

BROXURIDINE; CYCLIC GMP; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIBENCLAMIDE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LEVOSIMENDAN; LUCIFERASE; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICORANDIL; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATTENUATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG BLOOD VESSEL; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; RAT; REPORTER GENE; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL;

AIRWAY REMODELING; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; GERMANY; GLYBURIDE; HYDRAZONES; HYPERTENSION, PULMONARY; HYPOGLYCEMIC AGENTS; MYOCARDIAL CONTRACTION; NICORANDIL; POTASSIUM CHANNELS; PULMONARY CIRCULATION; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 79961025154     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-011-2254-9     Document Type: Article

References (49)

1. PM Hassoun L Mouthon JA Barbera S Eddahibi SC Flores F Grimminger PL Jones ML Maitland ED Michelakis NW Morrell JH Newman M Rabinovitch R Schermuly KR Stenmark NF Voelkel JX Yuan M Humbert 2009 Inflammation, growth factors, and pulmonary vascular remodeling J Am Coll Cardiol 54 S10 S19 19555853 10.1016/j.jacc.2009.04.006 1:CAS:528:DC%2BC3cXkvVOks7o%3D
2. M Humbert NW Morrell SL Archer KR Stenmark MR MacLean IM Lang BW Christman EK Weir O Eickelberg NF Voelkel M Rabinovitch 2004 Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 13S 24S 15194174 10.1016/j.jacc.2004.02.029 1:CAS:528:DC%2BD2cXlsFyhtrs%3D (Pubitemid 38759713)
3. RJ Barst JS Gibbs HA Ghofrani MM Hoeper VV McLaughlin LJ Rubin O Sitbon VF Tapson N Galie 2009 Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 S78 S84 19555861 10.1016/j.jacc.2009. 04.017 1:CAS:528:DC%2BC3cXkvVOksL4%3D
4. M Westphal A Morelli AH Van 2007 Dear levosimendan, the right ventricle will thank you! Crit Care Med 35 952 953 17421086 10.1097/01.CCM.0000257238. 75346.DB (Pubitemid 46407818)
5. 2+-sensitization Eur J Pharmacol 486 1 8 14751401 10.1016/j.ejphar.2003.12.006 1:CAS:528:DC%2BD2cXnvVOrsQ%3D%3D (Pubitemid 38130154)
6. P Bowman H Haikala RJ Paul 1999 Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization J Pharmacol Exp Ther 288 316 325 9862786 1:CAS:528: DyaK1MXisVyquw%3D%3D (Pubitemid 29113506)
7. J Pataricza I Krassoi J Hohn A Kun JG Papp 2003 Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery Cardiovasc Drugs Ther 17 115 121 12975592 10.1023/A:1025331617233 1:CAS:528:DC%2BD3sXmsFWitb8%3D (Pubitemid 37174684)
8. H Yokoshiki N Sperelakis 2003 Vasodilating mechanisms of levosimendan Cardiovasc Drugs Ther 17 111 113 14562823 10.1023/A:1025379400395 1:CAS:528:DC%2BD3sXmsFWitb4%3D (Pubitemid 37174683)
9. B Kota AS Prasad C Economides BN Singh 2008 Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure J Cardiovasc Pharmacol Ther 13 269 278 19087950 10.1177/1074248408324550 1:CAS:528:DC%2BD1MXivFGhsA%3D%3D
10. BJ De Witt IN Ibrahim E Bayer AM Fields TA Richards RE Banister AD Kaye 2002 An analysis of responses to levosimendan in the pulmonary vascular bed of the cat Anesth Analg 94 1427 1433 12032000 (table) (Pubitemid 34556617)
11. CH Bergh B Andersson U Dahlstrom K Forfang M Kivikko T Sarapohja B Ullman G Wikstrom 2010 Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers Eur J Heart Fail 12 404 410 20335355 10.1093/eurjhf/hfq032 1:CAS:528:DC%2BC3cXktVahsr4%3D
12. DJ Blackiston KA McLaughlin M Levin 2009 Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle Cell Cycle 8 3519 3528 19823012 10.4161/cc.8.21.9888
13. F Lang M Foller KS Lang PA Lang M Ritter E Gulbins A Vereninov SM Huber 2005 Ion channels in cell proliferation and apoptotic cell death J Membr Biol 205 147 157 16362503 10.1007/s00232-005-0780-5 1:CAS:528:DC%2BD2MXhtlWrsrjL (Pubitemid 41803692)
14. SJ Cook PJ Lockyer 2006 Recent advances in Ca(2+)-dependent Ras regulation and cell proliferation Cell Calcium 39 101 112 16343616 10.1016/j.ceca.2005.10.014 1:CAS:528:DC%2BD28XksFaj (Pubitemid 43013843)
15. A Di AB Malik 2010 TRP channels and the control of vascular function Curr Opin Pharmacol 10 127 132 20060363 10.1016/j.coph.2009.11.010 1:CAS:528:DC%2BC3cXjs12ntbw%3D
16. I Fleming R Busse 2003 Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase Am J Physiol Regul Integr Comp Physiol 284 R1 R12 12482742 1:CAS:528:DC%2BD3sXmvF2gsg%3D%3D
17. S Sakao K Tatsumi NF Voelkel 2009 Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation Respir Res 10 95 19825167 10.1186/1465-9921-10-95
18. PL Jones M Rabinovitch 1996 Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation Circ Res 79 1131 1142 8943951 1:CAS:528:DyaK28XnsVWhtrc%3D (Pubitemid 26404145)
19. RT Schermuly KP Kreisselmeier HA Ghofrani A Samidurai S Pullamsetti N Weissmann C Schudt L Ermert W Seeger F Grimminger 2004 Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension Circ Res 94 1101 1108 15031263 10.1161/01.RES.0000126050.41296.8E 1:CAS:528:DC%2BD2cXjt1ylu7s%3D (Pubitemid 38579705)
20. M Revermann E Barbosa-Sicard E Dony RT Schermuly C Morisseau G Geisslinger I Fleming BD Hammock RP Brandes 2009 Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats J Hypertens 27 322 331 19226702 10.1097/HJH.0b013e32831aedfa 1:CAS:528:DC%2BD1MXotVGnsg%3D%3D
21. K Schroder A Kohnen A Aicher EA Liehn T Buchse S Stein C Weber S Dimmeler RP Brandes 2009 NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells Circ Res 105 537 544 19679834 10.1161/CIRCRESAHA.109.205138
22. G Wiemer BA Scholkens RH Becker R Busse 1991 Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin Hypertension 18 558 563 1655653 1:CAS:528:DyaK3MXmslSgs7s%3D
23. B Fisslthaler AE Loot A Mohamed R Busse I Fleming 2008 Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin Circ Res 102 1520 1528 18483407 10.1161/CIRCRESAHA.108.172072 1:CAS:528:DC%2BD1cXmvFOhsbc%3D
24. M Hongo E Mawatari A Sakai Z Ruan T Koizumi F Terasawa Y Yazaki O Kinoshita U Ikeda T Shibamoto 2005 Effects of nicorandil on monocrotaline- induced pulmonary arterial hypertension in rats J Cardiovasc Pharmacol 46 452 458 16160596 10.1097/01.fjc.0000176728.74690.09 1:CAS:528:DC%2BD2MXpvFOkurY%3D (Pubitemid 41407572)
25. N Taira 1989 Nicorandil as a hybrid between nitrates and potassium channel activators Am J Cardiol 63 18J 24J 2525320 10.1016/0002-9149(89)90200-2 1:CAS:528:DyaL1MXltVygs7Y%3D (Pubitemid 19161045)
26. Y Minamiyama S Takemura S Hai S Suehiro S Okada Y Funae 2007 Nicorandil elevates tissue cGMP levels in a nitric-oxide-independent manner J Pharmacol Sci 103 33 39 17202748 10.1254/jphs.FP0061003 1:CAS:528:DC%2BD2sXhvFGnurc%3D (Pubitemid 46175593)
27. A Kuno SD Critz MV Cohen JM Downey 2007 Nicorandil opens mitochondrial K(ATP) channels not only directly but also through a NO-PKG-dependent pathway Basic Res Cardiol 102 73 79 16900442 10.1007/s00395-006-0612-5 1:CAS:528:DC%2BD2sXhvFymu7k%3D (Pubitemid 44939336)
28. N Ogawa M Saito A Mori K Sakamoto S Kametaka T Nakahara K Ishii 2007 Vasodilator effect of nicorandil on retinal blood vessels in rats Naunyn Schmiedebergs Arch Pharmacol 375 323 328 17525845 10.1007/s00210-007-0165-7 1:CAS:528:DC%2BD2sXmsFKitrg%3D (Pubitemid 46945335)
29. O Yildiz 2007 Vasodilating mechanisms of levosimendan: involvement of K+ channels J Pharmacol Sci 104 1 5 17452812 10.1254/jphs.CP0060010 1:CAS:528:DC%2BD2sXmt1Wrsbc%3D (Pubitemid 46790310)
30. JR Kersten MW Montgomery PS Pagel DC Warltier 2000 Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels Anesth Analg 90 5 11 10624967 10.1097/00000539-200001000-00003 1:CAS:528:DC%2BD3cXltFWitA%3D%3D (Pubitemid 30022959)
31. P Kaheinen P Pollesello J Levijoki H Haikala 2001 Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels J Cardiovasc Pharmacol 37 367 374 11300649 10.1097/00005344-200104000-00003 1:CAS:528:DC%2BD3MXisVSrtLw%3D (Pubitemid 32240418)
32. F Akar Y Manavbasi AI Parlar AT Ulus SF Katircioglu 2007 The gender differences in the relaxation to levosimendan of human internal mammary artery Cardiovasc Drugs Ther 21 331 338 17703356 10.1007/s10557-007-6047-x (Pubitemid 47598926)
33. RR Shah 2010 Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives Br J Pharmacol 159 58 69 19563537 10.1111/j.1476-5381.2009.00191.x 1:CAS:528:DC%2BC3cXhtFyntrg%3D
34. BL Copple CM Rondelli JF Maddox NC Hoglen PE Ganey RA Roth 2004 Modes of cell death in rat liver after monocrotaline exposure Toxicol Sci 77 172 182 14600277 10.1093/toxsci/kfh011 1:CAS:528:DC%2BD2cXnslOg (Pubitemid 38128658)
35. DM Kopustinskiene P Pollesello NE Saris 2001 Levosimendan is a mitochondrial K(ATP) channel opener Eur J Pharmacol 428 311 314 11689188 10.1016/S0014-2999(01)01350-4 1:CAS:528:DC%2BD3MXnvFCqsbc%3D (Pubitemid 33016646)
36. O Sareila R Korhonen H Auvinen M Hamalainen H Kankaanranta E Nissinen E Moilanen 2008 Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli Br J Pharmacol 155 884 895 19002103 10.1038/bjp.2008.328 1:CAS:528:DC%2BD1cXhtlGhsb7O
37. VP van Empel LJ De Windt 2004 Myocyte hypertrophy and apoptosis: a balancing act Cardiovasc Res 63 487 499 15276474 10.1016/j.cardiores.2004.02.013 (Pubitemid 38970193)
38. U Landmesser KC Wollert H Drexler 2009 Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res 81 519 527 19019834 10.1093/cvr/cvn317 1:CAS:528:DC%2BD1MXhtlKitLY%3D
39. F Perros P Dorfmuller R Souza I Durand-Gasselin V Godot F Capel S Adnot S Eddahibi M Mazmanian E Fadel P Herve G Simonneau D Emilie M Humbert 2007 Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension Eur Respir J 29 937 943 17182651 10.1183/09031936.00104706 1:CAS:528: DC%2BD2sXmsFOhtbc%3D (Pubitemid 46711898)
40. M Okawa-Takatsuji S Aotsuka M Fujinami S Uwatoko M Kinoshita M Sumiya 1999 Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein Clin Exp Immunol 116 174 180 10209523 10.1046/j.1365-2249.1999.00864.x 1:CAS:528:DyaK1MXis1CntrY%3D (Pubitemid 29170022)
41. O Sanchez E Marcos F Perros E Fadel L Tu M Humbert P Dartevelle G Simonneau S Adnot S Eddahibi 2007 Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 176 1041 1047 17823354 10.1164/rccm.200610-1559OC 1:CAS:528: DC%2BD2sXhsVekt7%2FK (Pubitemid 350127849)
42. Y Ikeda Y Yonemitsu C Kataoka S Kitamoto T Yamaoka K Nishida A Takeshita K Egashira K Sueishi 2002 Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats Am J Physiol Heart Circ Physiol 283 H2021 H2028 12384481 1:CAS:528:DC%2BD38XovVOmtbo%3D
43. Z Rakotoniaina P Guerard F Lirussi L Rochette M Dumas F Goirand M Bardou 2008 Celecoxib but not the combination of celecoxib + atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat Naunyn Schmiedebergs Arch Pharmacol 378 241 251 18542928 10.1007/s00210-008-0298-3 1:CAS:528:DC%2BD1cXpvVKgurg%3D
44. K Reinhart O Bayer F Brunkhorst M Meisner 2002 Markers of endothelial damage in organ dysfunction and sepsis Crit Care Med 30 S302 S312 12004252 10.1097/00003246-200205001-00021 1:CAS:528:DC%2BD38Xktlykt7c%3D
45. P Scheiermann D Ahluwalia S Hoegl A Dolfen M Revermann B Zwissler H Muhl KA Boost C Hofstetter 2009 Effects of intravenous and inhaled levosimendan in severe rodent sepsis Intensive Care Med 35 1412 1419 19367398 10.1007/s00134-009-1481-9
46. KA Boost S Hoegl A Dolfen H Czerwonka P Scheiermann B Zwissler C Hofstetter 2008 Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury Crit Care Med 36 1873 1879 18496375 10.1097/CCM.0b013e3181743e63 1:CAS:528:DC%2BD1cXmsFymsLs%3D
47. A Trikas C Antoniades G Latsios K Vasiliadou I Karamitros D Tousoulis C Tentolouris C Stefanadis 2006 Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure Eur J Heart Fail 8 804 809 16713737 10.1016/j.ejheart.2006.03.003 1:CAS:528: DC%2BD28Xht1eqtbjP (Pubitemid 44779417)
48. X Liu JY Wu F Zhou XL Sun HH Yao Y Yang JH Ding G Hu 2006 The regulation of rotenone-induced inflammatory factor production by ATP-sensitive potassium channel expressed in BV-2 cells Neurosci Lett 394 131 135 16257489 10.1016/j.neulet.2005.10.018 1:CAS:528:DC%2BD28XjsF2gsg%3D%3D (Pubitemid 43061474)
49. CR De P Libby HB Peng VJ Thannickal TB Rajavashisth MA Gimbrone Jr WS Shin JK Liao 1995 Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines J Clin Invest 96 60 68 10.1172/JCI118074